A Meta Analysis on Risks of Adverse Pregnancy Outcomes in *Toxoplasma gondii* Infection

Xue-Lan Li1*, Hai-Xia Wei1,*, Hao Zhang1,2, Hong-Juan Peng1*, David S. Lindsay3*

1 Department of Pathogen Biology, School of Public Health and Tropical Medicine, Southern Medical University, Guangzhou, Guangdong, the People's Republic of China, 2 Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital attached to Southern Medical University, Guangzhou, Guangdong, and the People's Republic of China, 3 Department of Biomedical Sciences & Pathobiology, VA-MD Regional College of Veterinary Medicine, Virginia Tech, Duck Pond Drive, Blacksburg, Virginia, United States of America

Abstract

**Objective:** Quantified risks of congenital *Toxoplasma gondii* infection and abnormal pregnancy outcomes following primary maternal infection were evaluated with meta-analysis based on published studies.

**Methods:** The related literatures were searched in multiple literature databases regardless of languages. Odds ratio (OR) and 95% confidence interval (CI) were used to evaluate the risks of vertical transmission of *Toxoplasma gondii* and abnormal pregnancy outcomes following primary maternal infection with meta-analysis.

**Results:** 53 of the 2632 searched literatures were included in our analysis. The incidence of abnormal pregnancy outcomes in *T. gondii* infected pregnant women (infected group) was significantly higher than that in the uninfected pregnant women (control group) (OR = 5.10; 95% CI, 3.85–6.75). *Toxoplasma gondii* infection rate in the abnormal-pregnancy-outcome group was significantly higher than in the normal-pregnancy group (OR = 3.71; 95% CI, 3.31–4.15). The pooled rate of vertical transmission was 20% (95% CI, 15%–26%) in maternal infection of *T. gondii*. The incidences of vertical transmission in women who were infected in the first, second or third trimester of pregnancy were 5% (95% CI, 2%–16%), 13% (95% CI, 7%–23%), and 32% (95% CI, 24%–41%), respectively. The rates of vertical transmission in women who were treated with spiramycin-only, PSF (pyrimethamine + sulfadiazine + folinic acid) or PS (pyrimethamine + sulfadiazine) combined with spiramycin, or other untypical treatments were 13% (95% CI, 7%–22%), 13% (95% CI, 7%–25%), and 24% (95% CI, 18%–32%), respectively.

**Conclusions:** *Toxoplasma gondii* infection can result in adverse pregnancy outcomes in pregnant women. The pooled rate of vertical transmission was 20% in maternal infection and the incidences of vertical transmission increased in the first, second or third trimester of pregnancy. The pooled rates of transmission in groups treated with spiramycin-only, PSF or PS combined with spiramycin, or other untypical treatments were not significantly different.

Introduction

*Toxoplasma gondii* is an intracellular protozoan parasite which is highly prevalent in humans and animals [1]. A wide variety of warm-blooded animals, including humans, can serve as the intermediate hosts of *T. gondii*, but its definitive host is limited to domestic cats and other felids [1,2]. People become infected by ingestion of *T. gondii* tissue cysts in infected meat or by ingestion of infective oocysts shed by cats in contaminated food or water [3]. Primary infection of *T. gondii* in pregnant women can cause vertical transmission of the parasite and result in miscarriage, stillbirth, premature birth, malformations and other adverse pregnancy outcomes. Children with congenital toxoplasmosis may exhibit clinical signs of hydrocephalus, mental retardation, eye disease and other severe sequelae [4,5]. Currently, congenital toxoplasmosis is believed to be the second most common seen fetal intrauterine infection [6]. Additionally, according to Torgerson and Mastroiacovo's study, the global annual prevalence of congenital toxoplasmosis was estimated to be 190 100 cases (95% confidence interval, CI: 179 300–206 300), which means the global burden of congenital toxoplasmosis was 1.20 million disability-adjusted life years (DALYs) (95% CI: 0.76–1.90) [7]. Hence, the poor health condition of children with congenital toxoplasmosis contributes to the heavy global health burden of children.
Women are usually symptomless when they acquire *T. gondii* infection in pregnancy. If maternal infection is detected, the mother usually receives treatment for toxoplasmosis and the fetus will face the risk of congenital infection. For treatment of *T. gondii* infection in pregnant women, the most commonly used drug is spiramycin because it can be absorbed efficiently and has little side effects to the fetus [8]. It is generally recommended to treat *Toxoplasma* infection with spiramycin in early trimesters, then change to PSF in the later trimesters [9].

Several studies have investigated the relationship between *T. gondii* infection and adverse pregnancy outcomes and the vertical transmission rate of *T. gondii*, but the parameters and methods used varied greatly in these studies. Because this is an extremely important health care issue, we used meta-analysis to evaluate the risks of vertical transmission and abnormal pregnancy outcomes in women experiencing primary infection with *T. gondii* during pregnancy.

**Materials and Methods**

**Search strategy**

Our study was performed according to the recommendations of the PRISMA Statement [10], which is available in (Checklist S1). We searched Pubmed, Embase, Google Scholar, ScienceDirect, and CNKI database, Chongqing VIP database, Wanfang academic journal full-text database for papers published up to May 2013. Studies were identified using combinations of the following search terms regardless of languages: “*Toxoplasma* OR *gondii* OR toxoplasmosis” AND “pregnancy infection” AND “adverse pregnancy outcome OR abortion OR stillbirth OR
abnormality OR fetal growth restriction OR FGR OR intrauterine growth retardation OR IUGR.

Literature citation inclusion and exclusion criteria

The literature citations were screened according to the following criteria. Inclusion criteria: (i) a case-control or cohort study or a survey with cases collected from clinical notes that related to our theme; (ii) the women in the control group were non-Toxoplasma-infected pregnant women and they were located in the same area as the women in the case group; (iii) the diagnosis of maternal T. gondii infection was based on seroconversion, parasite observation from cell culture or mouse ascites after inoculation of maternal blood, or PCR test of parasite DNA during gestation; (iv) the diagnosis of congenital Toxoplasma infection met one of the following standards: A. persistence of specific IgG in the child beyond 12 months or reappearance of IgG antibodies after cessation of antibiotic therapy, B. Toxoplasma specific IgM and/or IgA in cord blood and/or in neonatal blood (the purity of fetal blood was ascertained or the positive results were confirmed at least 7–10 days later), C. presence of parasite in amniotic fluid, placenta or fetal blood confirmed by inoculation to mice ascites, cell culture, or by PCR test. Literatures were excluded in the studies if (i) the paper was a review or a descriptive study; (ii) its subjects were not human beings but animals; (iii) the data was duplicate or the study only presented the final result without the raw data; (iv) the sample contained less than 40 participants or the number of participants in different groups was less than 10.

Data extraction

The following information was extracted from each study: first author, publication year, location of the study, demographic characteristics, the number of cases and controls, diagnostic methods of cases, treatment regimes of the infected women, pregnancy outcomes, and gestational age of infection. In some studies, not all of the data were extracted because a portion of the data had already been reported. And for the republished studies, only the most complete or recent study was included. Two reviewers independently collected the data and reached a consensus after a discussion on the literatures which were controversial.

Statistical analysis

The risk of T. gondii infection and various adverse pregnancy outcomes was estimated by odds ratio (OR) with the corresponding 95% confidence interval (95%CI). The pooled proportion of vertical transmission of toxoplasmosis with the corresponding 95%CI was calculated as well. It was considered statistically significant when P<0.05. In the forest plots, OR>1 represented a risk effect and OR<1 represented a protective effect. Statistical heterogeneity of results was appraised using a $\chi^2$-based Q test and I² statistic [11]. Only when P>0.10 and I²<50% was the heterogeneity considered not significant. The fixed-effects model was used when literature heterogeneity not existed; otherwise, the random-effects model was employed. Sensitivity analysis was conducted by modification of the inclusion criteria of this meta-analysis. The pooled proportion of vertical transmission of toxoplasmosis was calculated by Meta-Analysis Beta 3.13 software (Tufts Medical Center, Boston, MA). The other analyses were conducted using Stata software version 11.0 (Stata Corporation, College Station, TX, USA) and the publication bias was considered significant when P value was less than 0.05 in either Begg's test or Egger's test [12].

Table 1. Studies about abnormal pregnancy outcomes in T. gondii infected groups and control groups.

| First author | Year | Area | Cases/Controls | Diagnosis of Maternal Infection | Abortion* | Premature Birth* | Stillbirth* | Fetal Anomaly* | FGR* | Stillbirth* |
|--------------|------|------|---------------|--------------------------------|-----------|-----------------|------------|----------------|------|------------|
| Su CK        | 2002 | Guangxi | 64/932 | Positive IgM | 0.06/0.02 | 0.03/0.01 | - | 0.03/0.01 | 0.03/0.01 |
| Wen LZ       | 2003 | East China | 95/117 | Positive IgM | 0.04/0.02 | 0.03/0.01 | - | 0.03/0.01 | 0.03/0.01 |
| Liu J        | 2004 | Shandong | 76,986 | Positive IgM | 0.06/0.02 | 0.05/0.01 | - | 0.05/0.01 | 0.05/0.01 |
| Yan Q        | 2006 | Guangdong | 64,932 | Positive IgM and PCR | 0.07/0.02 | 0.06/0.01 | - | 0.06/0.01 | 0.06/0.01 |
| Suo QL       | 2009 | Hebei | 1285147 | Positive IgM and PCR | 0.07/0.02 | 0.06/0.01 | - | 0.06/0.01 | 0.06/0.01 |
| Wang J       | 2011 | Heilongjiang | 754,629 | Positive IgM | 0.07/0.02 | 0.06/0.01 | - | 0.06/0.01 | 0.06/0.01 |
| Fang L       | 2012 | Liaoning | 149,103 | Positive IgM | 0.07/0.02 | 0.06/0.01 | - | 0.06/0.01 | 0.06/0.01 |

Notes: # Cases, Toxoplasma-infected pregnant women; Controls, Non-infected pregnant women; * the data before and after the slash represent the rate of adverse pregnancy outcome in T.gondii infection groups and uninfected groups; - no statistics; ’’FGR’’, fetal growth restriction.
From the 2632 searched literatures, 53 were included and the results from these literatures were weighted [13–64,74], including 8 studies about adverse pregnancy outcomes when the mother was infected with *T. gondii* and with control groups for each [13–20], 25 studies about infection rate in adverse outcomes and normal groups [21–44,74], 21 studies about vertical transmission of the parasite [15,45–64] (Figure 1). Further, 7 papers provided the detailed information about the gestation age when the woman was infected [46,48,49,55,58,61,64]. Additionally, two papers involved mothers that gave birth to twins [51,53]. Some women received prenatal treatment in some studies [45,47,48,50,51,53–55,58,59,61,64]. Details about the first author, published year, area, diagnostic standard, number of cases and controls and treatment regimes in each literature were listed in Tables 1, 2, 3 and 4.

### Quantitative synthesis and heterogeneity analysis

1. **Comparison of the abnormal pregnancy chances between *T. gondii* infected and uninfected pregnant women.** The prevalence of abnormal pregnancy outcomes in *T. gondii* infected pregnant women (infected group) was significantly higher than in the uninfected pregnant women (control group) (P<0.05); the OR was 5.10 (95% CI, 3.85–6.75) analyzed with the random-effects model. Among these abnormal pregnancy outcomes, the prevalence of abortion, fetal anomaly, stillbirth, FGR (fetal growth restriction), and premature birth were all significantly higher in the infected group than that in the control group (P<0.05), with OR and 95% CI of 6.63 (4.56–9.65), 4.92 (2.26–10.73), 4.63 (2.72–7.90), 4.49 (2.10–9.57), and 3.49 (1.91–6.37), respectively (Figure 2). The detail analysis results were shown in Table 5.

2. **Comparison of *T. gondii* infection rate between abnormal pregnancy and normal pregnancy groups.** The infection rate of abnormal-pregnancy-outcome group was significantly higher than in the normal-pregnancy group (P<0.05), with an OR of 3.71 (95% CI, 3.31–4.15) analyzed with the random-effects model (Q = 74.62, p<0.0001, I² = 67.8%) (Figure 3).

3. **Chance of congenital *T. gondii* transmission occurring in maternal infection.** The rate of congenital transmission of *T. gondii* in maternal infection was 20% (95% CI, 15%–26%), which suggested that about 20% of infected mothers would transmit the parasite to fetus. The rate of vertical transmission in women who were infected in the first, second or third trimesters of pregnancy were 5% (95% CI, 2%–16%), 13% (95% CI, 7%–25%), and 32% (95% CI, 24%–41%), respectively (Figure 4). The detailed analysis results are shown in Table 6.
The pooled rate of congenital transmission of *T. gondii* occurring in women who received treatment was 16% (95% CI, 11%–24%), which suggested that about 16% of treated infected mothers would transmit the parasite to fetus. The rate of vertical transmission in women who received Spiramycin-only, PSF or PS in combination with spiramycin, or other untypical treatment were 13% (95% CI, 7%–22%), 13% (95% CI, 7%–25%), and 24% (95% CI, 18%–32%), respectively (Figure 5). The detailed analysis results are shown in Table 7.

### Sensitivity analysis

A sensitivity analysis was conducted to ascertain whether modification of the inclusion criteria of this meta-analysis affected the final results. On the analysis of the association between *T. gondii* infection and the abnormal pregnancy outcomes, the sensitivity analysis was carried out by excluding one single study each time and limiting the meta-analysis to studies with sample size more than 100. All the results were not materially altered.

### Publication bias

For prevalence of abortion between infected groups and uninfected groups and the *T. gondii* infection rate between abnormal pregnancy and normal pregnancy, the publication bias showed statistical significance (Begg’s test, *p* = 0.060–0.059; Egger’s test, *p* = 0.025–0.516) (Figure 6). In the other analysis, no publication bias was suggested.

### Discussion

Several studies have investigated the relationship between maternal infection with *T. gondii* and the adverse pregnancy outcomes including miscarriage, stillbirth, premature birth, and malformations. Our meta-analysis results confirmed this relationship and showed that miscarriage was the highest risk (OR = 6.63; 95% CI, 4.56–9.66) among the adverse pregnancy outcomes. Furthermore, a population-based study on the effects of congenital toxoplasmosis found out that infected babies were born or delivered earlier than uninfected babies, but the mechanism leading to a shorter length of gestation is unknown [65]. Additional studies are needed to determine whether adverse pregnancy outcomes after acquisition of *T. gondii* infection are related to a consequence of fetal infection or an effect of maternal infection. Additionally, mechanism of *T. gondii* causes placental inflammation and infects the fetus remains unknown.

### Table 3. Studies about the rate of vertical transmission when mother got infected in pregnancy.

| First author | Year | Area | Diagnostic Standards | Rate | Reference |
|--------------|------|------|----------------------|------|-----------|
| Berrebi A    | 1994 | Toulouse | Seroconversion Positive IgM, PCR or culture, clinical signs | 0.17 | [56] |
| Pratlong F   | 1994 | Montpellier | Seroconversion, high-titre IgG with IgM | 0.11 | [50] |
| Hohlfeld P   | 1994 | Paris | Seroconversion Positive IgM, PCR or culture | 0.07 | [54] |
| Dar FK       | 1997 | UAE | High-titre IgM | 0.38 | [52] |
| Jenum A      | 1998 | Norway | Seroconversion Persistent IgG beyond 12 months, positive PCR or culture | 0.23 | [64] |
| Gratzi R     | 1998 | Austria | Seroconversion, high-titre IgG and IgM | 0.22 | [51] |
| Foulon W     | 1999 | France | Seroconversion Persistent IgG beyond 12 months, reappearance of IgG after therapy | 0.44 | [57] |
| Robert-Gangneux F | 1999 | Paris | Seroconversion Persistent IgG beyond 12 months, positive PCR or culture | 0.25 | [59] |
| Naessens A   | 1999 | America | Seroconversion Persistent IgG beyond 12 months, reappearance of IgG after therapy | 0.32 | [57] |
| Lebech M     | 1999 | Denmark | Seroconversion Persistent IgG beyond 12 months, positive IgM and/or IgA | 0.19 | [49] |
| Gilbert R    | 2001 | EUR,Austria | Seroconversion Persistent IgG beyond 12 months, positive PCR or culture | 0.24 | [62] |
| Antsaklis A  | 2002 | Athens | Seroconversion Positive IgM, PCR or culture | 0.19 | [60] |
| Logar J      | 2002 | Ljubljana | High-titre IgG, high-titre IgM and/or IgA | 0.11 | [61] |
| Ricci M      | 2003 | Italy | Seroconversion, high-titre IgG and IgM | 0.11 | [55] |
| Mombro M     | 2003 | Italy | Seroconversion, positive cultures | 0.22 | [46] |
| Liu J        | 2004 | China | Positive PCR, high-titre IgM | 0.37 | [15] |
| Di Carlo P   | 2005 | Italy | Seroconversion Persistent IgG beyond 12 months, positive PCR | 0.19 | [58] |
| Buffolano W  | 2005 | Campania | Seroconversion Persistent IgG beyond 12 months | 0.34 | [63] |
| Berrebi A    | 2010 | Toulouse | Seroconversion Persistent IgG beyond 12 months | 0.17 | [53] |
| Hotop A      | 2012 | Germany | Seroconversion Persistent IgG beyond 12 months, positive PCR | 0.05 | [48] |
| Wollan M     | 2013 | Lyon | Seroconversion, high-titre IgG and IgM | 0.25 | [45] |

Notes: For the positive IgM/IgA results, the purity of fetal blood was ascertained or the positive results were confirmed at least 7-10 days later; Rate stands for vertical transmission rate caused by *T. gondii* infection.

doi:10.1371/journal.pone.0097775.t003
Our study also showed that later infection during pregnancy was more likely to result in congenital infection, which was consistent with Dunn’s and Foulon’s studies, but the 30% vertical transmission rate in the third trimester of pregnancy in our meta analysis was much lower than that of 60% in their studies [57,66], which possibly resulted from the small sample in their studies. Children with congenital Toxoplasma infection had more severe clinical symptoms when the mother acquired acute T. gondii infection during the first trimester than in the third trimester [54,67,68]. This may be due to the placental trophoblast, which is not conductive to the propagation of T. gondii and could prevent the parasite from crossing the placenta in early gestation [69]. But in later trimesters, the parasite is more likely to get through the placental barrier, so transmission is more frequent in later pregnancy than in earlier pregnancy. If the infection occurred in the first trimester, owing to the immature development and the low resistance of the fetus, the prevalence of sequelae may be higher than the infection happened in a later trimester [69,70].

The rate of vertical transmission in women who were treated with spiramycin only, PSF or PS in combination with spiramycin, 

| First Author | Year | Treatment | Infected Mother | Infected Baby | Rate | Reference |
|--------------|------|-----------|-----------------|--------------|------|-----------|
| Pratlong F   | 1994 | Spir-only | 190             | 20           | 0.11 | [50]      |
| Hohlfeld P   | 1994 | Spir-only | 2632            | 194         | 0.07 | [54]      |
| Gratl R      | 1998 | Spir-only | 12              | 1           | 0.08 | [51]      |
|              |      | PSF/Spir  | 37              | 10          | 0.27 | [51]      |
| Jenum A      | 1998 | PS/Spir   | 47              | 11          | 0.23 | [64]      |
| Robert-Gangneux F | 1999 | Spir-only | 110             | 27          | 0.25 | [59]      |
| Naessens A   | 1999 | Others¹   | 294             | 93          | 0.32 | [47]      |
| Logar J      | 2002 | PSF/Spir  | 100             | 11          | 0.11 | [61]      |
| Ricci M      | 2003 | PSF/Spir  | 141             | 16          | 0.11 | [55]      |
| Buffolano W  | 2005 | Spir-only | 74              | 12          | 0.16 | [58]      |
| Berrebi A    | 2010 | Others²   | 666             | 112         | 0.17 | [53]      |
| Hotop A      | 2012 | PSF/Spir  | 685             | 33          | 0.05 | [48]      |
| Wallon M     | 2013 | Others³   | 2048            | 513         | 0.25 | [45]      |

Notes: Spir-only, spiramycin only; PS/Spir, PS in combination with spiramycin; PSF/Spir, PSF in combination with spiramycin; Others, other untypical treatment, ¹ only 75% of infected women were administered to antibiotic treatment, the rest were conducted with other medicine; ² 80% of infected women were administered to pyrimethamine-sulfadoxine, 20% were taken with spiramycin; ³ PS alternated every 3 weeks with spiramycin before 1996, and then PS was taken continually.

doi:10.1371/journal.pone.0097775.t004

Figure 2. Forest plot of the relationship between T.gondii infection and adverse pregnancy outcomes. a. The odds ratio of the total abnormal pregnancy chance between Toxoplasma infected and uninfected pregnant women; b-f. The odds ratio of the different abnormal pregnancy outcomes between Toxoplasma infected and uninfected pregnant women. Scale: for value of odds ratio.
were 13% (95%CI, 7%–22%), and 13% (95%CI, 7%–25%), respectively. Comparing to Lebech M’s study, the transmission rate of untreated pregnant women was 19% (95%CI, 13%–27%) [49], so we speculated that there was a low risk of vertical transmission in treated women with *Toxoplasma* infection during pregnancy. However, the effect of the prenatal treatment remains vague as there was no clear evidence from biological studies that prenatal treatment would reduce the risk of congenital infection.

To prove whether the treatment regimes have a significant impact on pregnancy outcome, a clinical study with a large sample and an untreated comparison group is needed. To avoid unnecessary drug therapy and pregnancy termination, much effort had been put to find an effective, quick, safe and cheap method for prenatal diagnosis of maternal infection. Now it is available through PCR on amniotic fluid, which was confirmed to be the most reliable method with high sensitivity and high

| Outcomes          | Test of risk     | Test of heterogeneity | Model                  | Reference                          |
|-------------------|------------------|-----------------------|------------------------|------------------------------------|
|                   | Odds Ratio (95%CI) | P         | Q      | P     | I² (%) |                              |
| Abortion          | 6.63 (4.56 to 9.65) | <0.0001 | 4.76  | 0.04 | <0.01  | Fixed-effects model [14,15,17–20] |
| Fetal anomaly     | 4.92 (2.26 to 10.73) | <0.0001 | 15.30 | 0.01 | 67.3   | Random-effects model [13,14,16–19] |
| Stillbirth        | 4.63 (2.72 to 7.90) | <0.0001 | 3.11  | 0.80 | <0.01  | Fixed-effects model [13–19]    |
| FGR               | 4.49 (2.10 to 9.57) | <0.0001 | 0.58  | 0.75 | <0.01  | Fixed-effects model [14,15,18]  |
| Premature birth   | 3.49 (1.91 to 6.37) | <0.0001 | 12.95 | 0.04 | 53.7   | Random-effects model [13–18,20] |
| Total             | 5.10 (3.85 to 6.75) | <0.0001 | 14.76 | 0.04 | 52.6   | Random-effects model [13–20]   |

doi:10.1371/journal.pone.0097775.t005

![Figure 3. Odds ratio of *Toxoplasma* infection rate between abnormal pregnancy and normal pregnancy. Scale: for value of odds ratio. doi:10.1371/journal.pone.0097775.g003](image-url)
Figure 4. Proportion of congenital toxoplasmosis happening by mother infection. a, The rate of vertical transmission when mother got infected in pregnancy; b-d, The rate of vertical transmission in different pregnancy trimester. Scale: incidence of congenital toxoplasmosis.
doi:10.1371/journal.pone.0097775.g004

Table 6. Analysis results of the rate of vertical transmission when mother got infected in different trimester.

| Time          | Pooled Proportion (95%CI) | Test of risk | Test of heterogeneity | Model                     | Reference               |
|---------------|---------------------------|--------------|-----------------------|---------------------------|-------------------------|
|               |                           | P            | Q                     |                           |                         |
|               |                           |              |                       |                           |                         |
| First trimester | 0.05 (0.02 to 0.16)       | <0.0001      | 0.979                 | <0.001                   | 47.2                    | Random-effects model    | [48,49,55,56,61,64] |
| Second trimester | 0.13 (0.07 to 0.28)       | <0.0001      | 0.939                 | 0.004                    | 42.5                    | Random-effects model    | [46,48,55,56,61]    |
| Third trimester | 0.32 (0.24 to 0.41)       | <0.0001      | 0.827                 | 0.237                    | 13.9                    | Fixed-effects model     | [46,48,55,61,64]    |
| Total pregnancy | 0.20 (0.15 to 0.26)       | <0.0001      | 0.998                 | <0.001                   | 49.0                    | Random-effects model    | [15,45–64]           |

doi:10.1371/journal.pone.0097775.t006
Figure 5. Proportion of congenital toxoplasmosis happening when infected mother received prenatal treatment. a, The total rate of vertical transmission when mother received treatment; b-d, The rate of vertical transmission when mother received different treatment regimes. Scale: incidence of congenital toxoplasmosis.
doi:10.1371/journal.pone.0097775.g005

Table 7. Analysis results of the vertical transmission rate when infected mother got treatment in pregnancy.

| Treatment  | Test of risk | Test of heterogeneity | Model | Reference |
|------------|--------------|-----------------------|-------|-----------|
|            | Pooled Proportion (95%CI) |  P    |  Q    |  I² (%) |             |
| Spir-only  | 0.128 (0.070 to 0.223) | <0.0001 | 0.977 | <0.001 | 47.5 | Random-effects model | [50,51,54,58,59] |
| P/S        | 0.131 (0.065 to 0.245) | <0.0001 | 0.975 | <0.001 | 47.3 | Random-effects model | [48,51,55,61,64] |
| Others     | 0.239 (0.175 to 0.317) | <0.0001 | 0.967 | <0.001 | 48.2 | Random-effects model | [45,47,53] |
| Total      | 0.163 (0.110 to 0.235) | <0.0001 | 0.997 | <0.001 | 49.3 | Random-effects model | [45,47,48,50,51,53–55,58,59,61,64] |

Notes: Spir-only, spiramycin only; P/S, PS or PSF in combination with spiramycin; Others, other untypical treatment.
doi:10.1371/journal.pone.0097775.t007
Conclusion

This meta-analysis confirms the previous results that primary maternal infection of *T. gondii* during gestation plays a crucial role in adverse pregnancy outcomes. The incidences of abortion, fetal anomaly, stillbirth, fetal growth restriction, and premature birth were significantly higher in the infected group than in the control group, and showed in declining Odds Ratios. Reversely, *Toxoplasma gondii* infection rate in the abnormal-pregnancy-outcome group was significantly higher than in the normal-pregnancy group. The pooled rate of vertical transmission was 20% in maternal infection and the incidences of vertical transmission increased with the pregnancy time (the first, second or third trimester of pregnancy). Compared to the vertical transmission rate of 32% in the third trimester, the rate (5%) was much lower when the infection occurred in the first trimester. The pooled rate of vertical transmission in maternal infection received treatment was 16%, and the rates of treatment with spiramycin-only, PSF or PS combined with spiramycin, or other untypical treatments were not significantly different.

Supporting Information

Checklist S1 PRISMA checklist of this meta-analysis.

Author Contributions

Conceived and designed the experiments: HJP DSL. Performed the experiments: XLL HXW HZ. Analyzed the data: XLL HXW HZ. Contributed reagents/materials/analysis tools: XLL HXW HZ. Wrote the paper: XLL HXW.

References

1. Dubey JP (2010) Toxoplasmosis of Animals and Humans, Second Edition. Taylor & Francis.
2. Dubey JP (2009) History of the discovery of the life cycle of Toxoplasma gondii. Int J Parasitol 39:677–682.
3. Montoya JG, Liesenfeld O (2004) Toxoplasmosis. Lancet 363:1965–1976.
4. Jones JL, Lopez A, Wilson M, Schulkin J, Gibbs R (2001) Congenital toxoplasmosis: a review. Obstet Gynecol Surv 56:296–305.
5. Oharu TR, Remington JS, McLeod R, Alam A, Montoya JG (2011) Severe congenital toxoplasmosis in the United States: clinical and serologic findings in untreated infants. Pediatr Infect Dis J 30:1056–1061.
6. Bojar I, Szymanska J (2010) Environmental exposure of pregnant women to infection with Toxoplasma gondii—state of the art. Ann Agric Environ Med 17:209–214.
7. Torgerson PR, Mastromiaco P (2013) The global burden of congenital toxoplasmosis: a systematic review. Bull World Health Organ 91:501–508.
8. Desmonts G, Courveur J (1974) Toxoplasmosis in pregnancy and its transmission to the fetus. Bull N Y Acad Med 50:146–159.
9. Robert Koch Institute (2007) Guidelines toxoplasmosis. Epidemiol Bull 42:390–4.
10. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta- Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed.1000097
11. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558.
12. Egger M, Davey SG, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634.
13. Su CK, Wu ZB, Guo XB, Su RJ, Ma G (2002) The effects of toxoplasma infection on pregnancy in woman. Chinese journal of birth health & heredity 10:78–79.
14. Wen LZ, Liu LQ, Ao LM, Chen SH, Zeng WJ, et al. (2005) Effect of toxoplasma infection during pregnancy to the development of fetus and infant. Chin J Obstet Gynecol 38:331–333.
15. Liu J, Zhang L, Zhao XL, Ye GL, Cai XN, et al. (2004) Study on fetuses and infants’ abnormalities induced by toxoplasmosis infection in pregnancy. Chinese journal of child health care 12:313–315.
16. Yan Q, Zhang HY (2006) The effects of toxoplasma infection during pregnancy on fetus. Modern Medicine & Health 22:1654–1655.
17. Yuan WY, Liu XH, Yu CY, Zhao S, Zhao Q, et al. (2009) Follow up and observation on effect of toxoplasma gondii infection during pregnancy on...
73. Wallon M, Peyron F, Cornu C, Vinault S, Abrahamowicz M, et al. (2013) Congenital toxoplasma infection: monthly prenatal screening decreases transmission rate and improves clinical outcome at age 3 years. Clin Infect Dis 56:1223–1231.

74. Aljumali ZKM, Alsharzai AM (2013) Risk factors for bad obstetric history in Kirkuk women, Iraq. Int J Infect Microbiol 2(3):70–77